Thromb Haemost 1982; 47(01): 76
DOI: 10.1055/s-0038-1657131
Letter to the Editor
Schattauer GmbH Stuttgart

Synergism Between Prostacyclin (PGI2) and Prazosin on Human Platelet Aggregation

P K Moore
Department of Pharmacology, Chelsea College, Manresa Road, London SW3 6LX, U.K.
› Author Affiliations
Further Information

Publication History

Received 31 August 1981

Accepted 23 September 1981

Publication Date:
13 July 2018 (online)

 
  • References

  • 1 Hoffman BB, De Lean A, Wood CL, Schocken DD, Lefkowitz RJ. Alpha adrenergic receptor subtypes: quantitative assessment by ligand binding. Life Sci 1979; 24: 1739-1746
  • 2 Scrutton MC, Grant JA. Novel α2-adrenoceptors primarily responsible for inducing human platelet aggregation. Nature 1979; 207: 659-661
  • 3 Hsu CY, Knapp DR, Halushka PV. The effects of alpha adrenergic agents on human platelet aggregation. J Pharm Exp Ther 1979; 208: 366-370
  • 4 Pogliani E, Fantasia R, Colombi M, Praga C. Synergic effect of prostacyclin (PGI]2) and ±-blocking agent on adrenalin-induced human platelet aggregation. Thromb Haemostas 1980; 44: 106
  • 5 Hoult JRS, Lofts FJ, Moore PK. Stability of prostacyclin in plasma and its transformation by platelets to a stable spasmogenic product. Br J Pharmac 1981; 73: 250P
  • 6 Hess HJ. Biochemistry and structure activity studies with prazosin. In: Cotton DWK. ed. Prazosin: Evaluation of a new antihypertensive drug.4–15. Excerpta Medica: Amsterdam; 1974
  • 7 Oates HF, Graham RM, Stokes GS. Mechanism of the hypotensive action of prazosin. Arch Int Pharmacodyn Ther 1977; 277: 411-413
  • 8 Wood AJ, Bolli B, Simpson FO. Prazosin in normal subjects: plasma levels, blood pressure and heart rate. Br J Clin Pharmacol 1976; 1: 199-201